Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction

• Published in: Archives of surgery (Chicago. 1960) Vol. 145; no. 9; p. 880
• Main Authors: Warren Peled, Anne, Itakura, Kaoru, Foster, Robert D, Hamolsky, Debby, Tanaka, Janet, Ewing, Cheryl, Alvarado, Michael, Esserman, Laura J, Hwang, E Shelley
• Format: Journal Article
• Language: English
• Published: United States 01-09-2010
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Breast Implantation; Breast Neoplasms - drug therapy; Breast Neoplasms - surgery; Chemotherapy, Adjuvant; Female; Humans; Mammaplasty; Middle Aged; Postoperative Complications - epidemiology; Postoperative Complications - prevention & control; Reoperation - statistics & numerical data; Surgical Wound Infection - epidemiology; Tissue Expansion Devices; Wound Healing - drug effects
• ISSN: 1538-3644
• DOI: 10.1001/archsurg.2010.163

To determine the impact of chemotherapy and the timing of chemotherapy on postoperative outcomes after mastectomy and immediate breast reconstruction.
Retrospective review.
University tertiary care institution.
One hundred sixty-three consecutive patients undergoing mastectomy and immediate breast reconstruction.
Systemic chemotherapy for breast cancer.
Postoperative complications following mastectomy and immediate breast reconstruction.
One hundred sixty-three patients underwent mastectomy and immediate breast reconstruction during the study period, with a mean postoperative follow-up of 19.2 months. Sixty-six percent of the patients had expander/implant reconstruction, while 33% underwent autologous reconstruction. Fifty-seven patients received neoadjuvant chemotherapy and 41 received postoperative chemotherapy. Eighteen patients (44%) in the adjuvant chemotherapy cohort developed postoperative infections, compared with 13 patients (23%) in the neoadjuvant chemotherapy group and 16 patients (25%) who did not receive any chemotherapy (P = .05). Overall, 31% of patients had a complication requiring an unplanned return to the operating room; this rate did not differ between groups (P = .79). Of patients who underwent expander/implant reconstruction, 8 women (26%) in the neoadjuvant chemotherapy cohort, 7 women (22%) in the adjuvant chemotherapy cohort, and 8 women (18%) without chemotherapy required expander or implant removal (P = .70).
Although the highest rate of surgical site infections was in the adjuvant chemotherapy group, there were no differences between groups with respect to unplanned return to the operating room, expander loss, and donor-site complications. Neither the inclusion of chemotherapy nor the timing of its administration significantly affected the complication rates after mastectomy and immediate breast reconstruction in this population.